

**MEDICAID PHARMACY PRIOR AUTHORIZATION ADVISORY COMMITTEE**  
**Recommendations Summary**  
**November 6, 2013**

**In Attendance:**

	Committee Member	Yes or No
1	Rosanne Barber	No
2	James Boblin M.D.	Yes
3	Ward Brown, M.D.	No
4	Catherine Decker PharmD	Yes
5	Ronald Diamond, M.D.	Yes
6	Lawrence Fleming M.D.	Yes
7	Kevin Izard M.D.	No
8	Steve Maike RPh	Yes
9	William E. Raduege, M.D.	Yes
10	Pat Towers	Yes
11	Alicia Walker PharmD	Yes
12	Michael Witkovsky M.D.	Yes

**NOVEMBER 2013 THERAPEUTIC DRUG CLASS**

ANTIHISTAMINES, MINIMALLY SEDATING

BRONCHODILATORS, BETA AGONIST

COPD AGENTS

GLUCOCORTICOIDS, INHALED

LEUKOTRIENE MODIFIERS

COUGH AND COLD/NARCOTICS

EPINEPHRINE, SELF-INJECTED

INTRANASAL RHINITIS AGENTS

ANTIHYPERURICEMICS, ORAL

BILE SALTS

HISTAMINE II RECEPTOR BLOCKERS

OPHTHALMIC ANTIBIOTIC/STEROID COMBINATIONS

OPHTHALMIC ANTIBIOTICS

OPHTHALMIC ANTIINFLAMMATORIES

OPHTHALMICS FOR ALLERGIC CONJUNCTIVITIS

OPHTHALMICS, GLAUCOMA AGENTS

OTIC ANTIBIOTICS

OTIC ANTI-INFECTIVES

ANTIPSORIATICS, TOPICAL

IMMUNOMODULATORS FOR ATOPIC DERMATITIS

STEROIDS, TOPICAL-LOW POTENCY

STEROIDS, TOPICAL-MEDIUM POTENCY

STEROIDS, TOPICAL-HIGH POTENCY

STEROIDS, TOPICAL-VERY HIGH POTENCY

CYTOKINE AND CAM ANTAGONISTS

NSAIDS

NEUROPATHIC PAIN (ANALGESICS/ANESTHETICS TOPICAL AND FIBROMYALGIA)

ALZHEIMER'S AGENTS

ANTICONVULSANTS

ANTIDEPRESSANTS, OTHER

ANTIDEPRESSANTS, SSRIs

ANTIPARKINSON'S AGENTS

ANTIPSYCHOTICS

SEDATIVE HYPNOTICS

STIMULANTS AND RELATED AGENTS

### NEW CLASSES

ANTIHYPERTENSIVES, SYMPATHOLYTICS

ANXIOLYTICS

ANTIPSORIATICS, ORAL

IMMUNOMODULATORS, TOPICAL

## Discussion:

Upon conclusion of public testimony, Kim Wohler reminded committee members of the creation of a new department guidelines document for the Wisconsin Medicaid Pharmacy Prior Authorization Advisory Committee located on the Forward Health portal.

Rachel Currans-Henry drew the committee's attention to the Mental Health Drug Advisors (MHDA) Preliminary Recommendations Response document from the October 31, 2013 meeting. In anticipation of the approaching release of generic Cymbalta, one MHDA consumer advocate member expressed concern with the department's Brand Medically Necessary (BMN) policy because of previous personal experience with the use of a generic antidepressant drug. Written testimony from Mental Health America of Wisconsin detailing the discussion from the MHDA meeting was also discussed.

- One committee member expressed that a single anecdotal experience shouldn't drive all classes. The only way to know a particular response is to try the generic.
- One committee member stated that data shows that some individuals that are stabilized on a brand medication and required to try a new generic for trial and failure requirements, may find upon return to the original brand medication that it does not work as well for them.
- One committee member stated that some people do really well with generic drugs and some do not. There are clearly some documented adverse responses, but this is not routinely an issue. There are minor dose differences between manufacturers. When pharmacies fluctuate between generic manufacturers this may create some issues. It may be more appropriate to allow rapid access through Stat-PA, rather than grandfathering on an expensive brand name drug. Even if a brand and generic drug are manufacturer by the same manufacturer, there can be manufacturing differences.
- One committee member stated that even individual manufacturing of a brand name drug may vary from batch to batch produced. Variability happens and there is an expected acceptable variability level.
- One committee member stated that requiring a member to change from a brand name drug to its generic equivalent should not be treated the same as changing to a completely different drug, where grandfathering may be more appropriate.
- One committee member stated that there are some select issues, but this is not the case with most drugs. It is common practice to prefer generics over brand name drugs in the industry.

The committee's attention was drawn to the staff recommendation to prefer triazolam for the Sedative Hypnotics class. Written testimony from the dental community expressed concern, that requiring them to obtain prior authorization prior to dental procedure use was creating an unnecessary burden. The MHDA group did not provide a specific response to the recommendation.

- One committee member asked staff if it was possible to allow access only for dental procedures. Staff responded that there would not be a systematic way to enforce this.
- One committee member expressed concern with preferring a drug with the potential for abuse and that has been banned in Europe.
- Some committee members asked if dispensing one pill could be made part of the dental procedure.
- One committee member stated that if triazolam was preferred it should be monitored closely.

**Recommendations Summary:**

<b>ANTI-HISTAMINES, MINIMALLY SEDATING</b>						
<b>Brand Name</b>	<b>Current Market Share</b>	<b>Current PDL Status</b>	<b>PDL Recommendation</b>	<b>COMMITTEE RECOMMENDATIONS</b>	<b>STATE MODIFICATIONS</b>	<b>SECRETARY MODIFICATIONS</b>
LORATADINE TABLETS OTC (ORAL)	39.3%	ON	Yes-Generic			
CETIRIZINE TABLETS OTC (ORAL)	34.4%	ON	Yes-Generic			
CETIRIZINE SOLUTION (ORAL)	10.5%	ON	Yes-Generic			
CETIRIZINE SOLUTION OTC (ORAL)	3.7%	ON	Yes-Generic			
LORATADINE SOLUTION OTC (ORAL)	6.7%	ON	Yes-Generic			
LORATADINE-D OTC (ORAL)	3.4%	ON	Yes-Generic			
LEVOCETIRIZINE TABLETS (ORAL)	0.3%	OFF	No-Generic			
CETIRIZINE-D OTC (ORAL)	1.4%	ON	Yes-Generic			
CLARINEX SYRUP (ORAL)	0.0%	OFF	No			
SEMPREX-D (ORAL)	0.0%	OFF	No			
CLARINEX TABLET (ORAL)	0.0%	OFF	No			
CLARINEX-D 24 HOUR (ORAL)	0.0%	OFF	No			
CLARINEX-D 12 HOUR (ORAL)	0.0%	OFF	No			
LEVOCETIRIZINE SOLUTION (ORAL)	0.1%	OFF	No-Generic			
XYZAL SOLUTION (ORAL)	0.0%	OFF	No			
DESLORATADINE (ORAL)	0.1%	OFF	No-Generic			
DESLORATADINE ODT (ORAL)	0.0%	NR	No-Generic			

- Discussion: None
- Catherine Decker made a motion to accept staff recommendation as presented.
  - Second – Lawrence Fleming
  - All members were in favor of the motion.
  - Motion passes.

BRONCHODILATORS, BETA AGONIST						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
PROVENTIL HFA (INHALATION)	11.4%	ON	Yes			
ALBUTEROL SYRUP (ORAL)	0.2%	ON	Yes-Generic			
METAPROTERENOL SYRUP (ORAL)	0.0%	OFF	No-Generic			
PROAIR HFA (INHALATION)	71.5%	ON	Yes			
ALBUTEROL NEB SOLN 2.5MG/3 ML (INHALATION)	13.6%	ON	Yes-Generic			
ALBUTEROL NEB SOLN 2.5 MG/0.5 ML (INHALATION)	0.0%	ON	Yes-Generic			
VENTOLIN HFA (INHALATION)	0.6%	OFF	No			
TERBUTALINE (ORAL)	0.0%	ON	Yes-Generic			
FORADIL (INHALATION)	0.3%	ON	Yes			
ALBUTEROL TABLET (ORAL)	0.0%	ON	Yes-Generic			
XOPENEX HFA (INHALATION)	0.5%	OFF	No			
XOPENEX NEB SOLN (INHALATION)	0.1%	OFF	No			
ALBUTEROL NEB SOLN 100 MG/20 ML (INHALATION)	0.2%	ON	Yes-Generic			
ALBUTEROL NEB SOLN 0.63, 1.25 MG (INHALATION)	0.8%	OFF	No-Generic			
SEREVENT (INHALATION)	0.1%	OFF	No			
MAXAIR (INHALATION)	0.2%	ON	Yes			
METAPROTERENOL TABLET (ORAL)	0.0%	OFF	No-Generic			
ALBUTEROL ER (ORAL)	0.0%	ON	Yes-Generic			
ARCAPTA NEOHALER (INHALATION)	0.0%	OFF	No			
BROVANA (INHALATION))	0.1%	OFF	No			
LEVALBUTEROL NEB SOLN CONC (INHALATION)	0.0%	OFF	No-Generic			
PERFORMIST (INHALATION)	0.1%	OFF	No			
XOPENEX NEB SOLN CONC (INHALATION)	0.0%	OFF	No			
LEVALBUTEROL NEB SOLN (INHALATION)	0.3%	OFF	No-Generic			

- Discussion: None
- Ron Diamond made a motion to accept staff recommendations as presented.
  - Second –William Raduege
  - All members were in favor of this motion.
  - Motion passes

COPD AGENTS						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
IPRATROPIUM NEBULIZER (INHALATION)	3.6%	ON	Yes-Generic			
COMBIVENT (INHALATION)	7.1%	ON	Yes			
IPRATROPIUM/ALBUTEROL (INHALATION)	18.9%	ON	Yes-Generic			
ATROVENT HFA (INHALATION)	4.3%	ON	Yes			
SPIRIVA (INHALATION)	43.2%	ON	Yes			
COMBIVENT RESPIMAT (INHALATION)	20.7%	ON	Yes			
DALIRESP (ORAL)	1.8%	ON	Yes			
TUDORZA PRESSAIR (INHALATION)	0.5%	NR	No			

- Discussion: None
- Catherine Decker made a motion to accept staff recommendations as presented.
  - Second –William Raduege
  - All members were in favor of this motion.
  - Motion passes

GLUCOCORTICOIDS, INHALED						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
ASMANEX (INHALATION)	1.5%	ON	Yes			
QVAR (INHALATION)	6.7%	ON	Yes			
FLOVENT HFA (INHALATION)	24.0%	ON	Yes			
FLOVENT DISKUS (INHALATION)	0.9%	ON	Yes			
PULMICORT FLEXHALER (INHALATION)	1.0%	ON	Yes			
ADVAIR DISKUS (INHALATION)	40.8%	ON	Yes			
SYMBICORT (INHALATION)	12.4%	ON	Yes			
DULERA (INHALATION)	2.3%	ON	Yes			
ADVAIR HFA (INHALATION)	4.5%	ON	Yes			
ALVESCO (INHALATION)	0.1%	OFF	No			
PULMICORT 0.25, 0.5 MG RESPULES (INHALATION)	0.1%	OFF	Yes			
BUDESONIDE 0.25, 0.5 MG RESPULES	5.4%	OFF	No-Generic			

(INHALATION)						
PULMICORT 1 MG RESPULES (INHALATION)	0.3%	OFF	Yes			

- Discussion: None
- William Raduege made a motion to accept staff recommendations as presented.
  - Second –Michael Witkovsky
  - All members were in favor of this motion.
  - Motion passes

LEUKOTRIENE MODIFIERS						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
MONTELUKAST TABLET (ORAL)	58.5%	ON	Yes-Generic			
MONTELUKAST TAB CHEW (ORAL)	40.8%	ON	Yes-Generic			
ZAFIRLUKAST (ORAL)	0.4%	OFF	No-Generic			
SINGULAIR GRANULES (ORAL)	0.0%	OFF	No			
MONTELUKAST GRANULES (ORAL)	0.2%	OFF	No-Generic			
ZYFLO (ORAL)	0.0%	OFF	No			
ZYFLO CR (ORAL)	0.1%	OFF	No			

- Discussion: None
- Pat Towers made a motion to accept staff recommendations as presented.
  - Second –Catherine Decker
  - All members were in favor of this motion.
  - Motion passes

COUGH AND COLD, NARCOTIC						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
GUAIFENESIN/CODEINE SYRUP OTC (ORAL)	50.2%	ON	Yes-Generic			
PROMETHAZINE/CODEINE SYRUP (ORAL)	47.2%	ON	Yes-Generic			
RELCOF-C (ORAL)	0.0%	OFF	No-Generic			
M-END WC (ORAL)	0.0%	OFF	No-Generic			
M-END PE (ORAL)	0.0%	OFF	No-Generic			
PRO-RED AC OTC (ORAL)	0.0%	OFF	No-Generic			
PRO-CLEAR AC OTC (ORAL)	0.0%	OFF	No-Generic			



M-END MAX D OTC (ORAL)	0.0%	OFF	No			
Z-TUSS E OTC (ORAL)	0.0%	OFF	No-Generic			
TRYMINE CG OTC (ORAL)	0.0%	OFF	No-Generic			
CAPCOF (ORAL)	0.0%	OFF	No			
Z-TUSS AC OTC (ORAL)	0.0%	OFF	No-Generic			
TUSSIONEX PENNKINETIC SUSPENSION (ORAL)	0.1%	OFF	No			
MAR-COF CG (ORAL)	0.0%	OFF	No-Generic			
MAR-COF BP (ORAL)	0.0%	OFF	No-Generic			
RYDEX OTC (ORAL)	0.0%	OFF	No-Generic			
LORTUSS EX OTC (ORAL)	0.0%	OFF	No-Generic			
VANACOF CD (ORAL)	0.0%	OFF	No-Generic			
PHENYLHISTINE DH OTC (ORAL)	0.0%	OFF	No-Generic			
CODAR GF (ORAL)	0.0%	OFF	No			
CODAR AR (ORAL)	0.0%	OFF	No			
TUSNEL C(ORAL)	0.0%	OFF	No-Generic			
PROMETHAZINE VC/CODEINE SYRUP (ACTAVIS) (ORAL)	0.0%	ON	Yes-Generic			
CODAR D (ORAL)	0.0%	OFF	No			
PROMETHAZINE VC/CODEINE SYRUP (QUALITEST) (ORAL)	1.2%	ON	Yes-Generic			
TRICODE GF (ORAL)	0.0%	OFF	No			
TRICODE AR (ORAL)	0.0%	OFF	No			
POLY-TUSSIN AC OTC (ORAL)	0.0%	NR	No-Generic			
HYDROCODONE/HOMATROPINE SYRUP (ORAL)	0.1%	OFF	No-Generic			
MAXIFED-G CD (ORAL)	0.0%	OFF	No-Generic			
MAXIFED CD (ORAL)	0.0%	OFF	No-Generic			
MAXIFED-G CDX (ORAL)	0.0%	OFF	No-Generic			
MAXIFLU CD (ORAL)	0.0%	OFF	No-Generic			
MAXIPHEN CD (ORAL)	0.0%	OFF	No-Generic			
MAXIFED CDX (ORAL)	0.0%	OFF	No-Generic			
MAXIFLU CDX (ORAL)	0.0%	OFF	No-Generic			
MAXIPHEN CDX (ORAL)	0.0%	OFF	No-Generic			
J-MAX DHC (ORAL)	0.0%	OFF	No-Generic			
PHENFLU CD (ORAL)	0.0%	OFF	No-Generic			
PHENFLU CDX (ORAL)	0.0%	OFF	No-Generic			
J-COF DHC (ORAL)	0.0%	OFF	No-Generic			
CHERATUSSIN DAC OTC (ORAL)	0.0%	OFF	No-Generic			
DEX-TUSS OTC (ORAL)	0.6%	ON	No-Generic			
REZIRA (ORAL)	0.0%	OFF	No			

ZUTRIPRO (ORAL)	0.0%	OFF	No			
HYDROCODONE/CHLORPHENIRAMINE SUSP (ORAL)	0.6%	OFF	No-Generic			
VITUZ SOLUTION (ORAL)	0.0%	NR	No			

- Discussion: None
- William Raduege made a motion to accept staff recommendations as presented.
  - Second – Steve Maike
  - All members were in favor of this motion
  - Motion passes

EPINEPHRINE, SELF-INJECTED						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
EPINEPHRINE (INJECTION)	0.0%	NR	No-Generic			
EPIPEN (INTRAMUSC)	75.1%	ON	Yes			
EPIPEN JR (INTRAMUSC)	24.9%	ON	Yes			
AUVI-Q (INTRAMUSC)	0.0%	NR	No			

- Discussion: Michael Witkovsky stated that the Auvi-Q has great technology and the committee needs to recognize that.
- Ronald Diamond and Steve Maike seconded the committee’s recognition of the benefits of the technology, but stated that it was not cost-effective to consider at this time. The committee would like to encourage the manufacturer to consider price in subsequent years.
- Pat Towers made a motion to accept staff recommendations as presented.
  - Second –William Raduege
  - All members were in favor of this motion.
  - Motion passes

INTRANASAL RHINITIS AGENTS						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
ASTELIN (NASAL)	1.50	ON	Yes			
NASONEX (NASAL)	14.2%	ON	Yes			
OMNARIS (NASAL)	0.1%	OFF	No			
IPRATROPIUM (NASAL)	1.8%	ON	Yes-Generic			
FLUTICASONE (NASAL)	78.0%	ON	Yes-Generic			
PATANASE (NASAL)	1.0%	ON	Yes			
ASTEPRO (NASAL)	0.8%	ON	Yes			
BECONASE AQ (NASAL)	0.3%	ON	Yes			
QNASL (NASAL)	0.1%	OFF	No			

VERAMYST (NASAL)	0.5%	OFF	No			
ZETONNA (NASAL)	0.1%	OFF	No			
FLUNISOLIDE (NASAL)	0.1%	OFF	No-Generic			
AZELASTINE (NASAL)	0.1%	OFF	No-Generic			
RHINOCORT AQUA (NASAL)	0.2%	OFF	No			
DYMISTA (NASAL)	0.0%	OFF	No			
TRIAMCINOLONE (NASAL)	0.0%	OFF	No-Generic			
NASACORT AQ (NASAL)	1.1%	ON	No			

- Discussion: None
- Lawrence Fleming made a motion to accept staff recommendations as presented.
  - Second –Catherine Decker
  - All members were in favor of this motion.
  - Motion passes

ANTIHYPERURICEMICS						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
ALLOPURINOL (ORAL)	83.4%	ON	Yes-Generic			
PROBENECID / COLCHICINE (ORAL)	2.6%	ON	Yes-Generic			
PROBENECID (ORAL)	1.6%	ON	Yes-Generic			
ULORIC (ORAL)	5.5%	OFF	No			
COLCRYS (ORAL)	6.9%	OFF	No			

- Discussion: None
- William Raduege made a motion to accept staff recommendations as presented.
  - Second –Michael Witkovsky
  - All members were in favor of this motion.
  - Motion passes

BILE SALTS						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
URSODIOL 300 MG CAPSULE (ORAL)	76.8%	ON	Yes-Generic			
URSODIOL TABLET (ORAL)	23.2%	ON	Yes-Generic			
CHENODAL (ORAL)	0.0%	OFF	No-Generic			

- Discussion: None
- Michael Witkovsky made a motion to accept staff recommendations as presented.

- Second –William Raduege
- All members were in favor of this motion.
- Motion passes

<b>HISTAMINE II RECEPTOR BLOCKER</b>						
<b>Brand Name</b>	<b>Current Market Share</b>	<b>Current PDL Status</b>	<b>PDL Recommendation</b>	<b>COMMITTEE RECOMMENDATIONS</b>	<b>STATE MODIFICATIONS</b>	<b>SECRETARY MODIFICATIONS</b>
FAMOTIDINE TABLET (ORAL)	20.1%	ON	Yes-Generic			
RANITIDINE TABLET (ORAL)	56.9%	ON	Yes-Generic			
RANITIDINE SYRUP (ORAL)	18.1%	ON	Yes-Generic			
CIMETIDINE TABLET (ORAL)	1.4%	ON	Yes-Generic			
CIMETIDINE SOLUTION (ORAL)	0.2%	ON	Yes-Generic			
NIZATIDINE CAPSULE (ORAL)	0.3%	OFF	No-Generic			
RANITIDINE CAPSULE (ORAL)	2.2%	OFF	No-Generic			
NIZATIDINE SOLUTION (ORAL)	0.2%	OFF	No-Generic			
FAMOTIDINE SUSPENSION (ORAL)	0.6%	OFF	No-Generic			

- Discussion: None
- William Radeuge made a motion to accept staff recommendations as presented.
  - Second –Pat Towers
  - All members were in favor of this motion.
  - Motion passes

<b>OPHTHALMIC ANTIBIOTIC-STEROID COMBINATIONS</b>						
<b>Brand Name</b>	<b>Current Market Share</b>	<b>Current PDL Status</b>	<b>PDL Recommendation</b>	<b>COMMITTEE RECOMMENDATIONS</b>	<b>STATE MODIFICATIONS</b>	<b>SECRETARY MODIFICATIONS</b>
TOBRADEX SUSPENSION (OPHTHALMIC)	29.1%	ON	Yes			
BLEPHAMIDE (OPHTHALMIC)	1.5%	ON	Yes			
TOBRADEX ST (OPHTHALMIC)	0.0%	OFF	No			
BLEPHAMIDE S.O.P. (OPHTHALMIC)	0.5%	ON	Yes			
TOBRADEX OINTMENT (OPHTHALMIC)	14.7%	ON	Yes			
PRED-G DROPS SUSP (OPHTHALMIC)	0.1%	ON	Yes			
SULFACETAMIDE / PREDNISOLONE (OPHTHALMIC)	2.6%	ON	Yes-Generic			
NEOMYCIN/POLYMYXIN/DEXAMET HASONE (OPHTHALMIC)	42.1%	ON	Yes-Generic			
PRED-G OINT. (OPHTHALMIC)	0.1%	ON	Yes			

ZYLET (OPHTHALMIC)	6.4%	ON	No			
NEOMYCIN/BACITRACIN/POLY/HC (OPHTHALMIC)	0.0%	OFF	No-Generic			
TOBRAMYCIN/DEXAMETHASONE SUSPENSION (OPHTHALMIC)	2.7%	OFF	No-Generic			
NEOMYCIN/POLYMYXIN/HC (OPHTHALMIC)	0.1%	OFF	No-Generic			

- Discussion: None
- Ronald Diamond made a motion to accept staff recommendations as presented.
  - Second –William Raduege
  - All members were in favor of this motion.
  - Motion passes

OPHTHALMIC ANTIBIOTICS						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
GENTAMICIN DROPS (OPHTHALMIC)	9.5%	ON	Yes-Generic			
OFLOXACIN (OPHTHALMIC)	6.4%	ON	Yes-Generic			
CIPROFLOXACIN SOLUTION (OPHTHALMIC)	9.2%	ON	Yes-Generic			
MOXEZA (OPHTHALMIC)	0.3%	ON	Yes			
POLYMYXIN/TRIMETHOPRIM (OPHTHALMIC)	26.5%	ON	Yes-Generic			
TOBEX OINTMENT (OPHTHALMIC)	0.4%	ON	Yes			
VIGAMOX (OPHTHALMIC)	12.4%	ON	Yes			
TOBRAMYCIN (OPHTHALMIC)	6.9%	ON	Yes-Generic			
ERYTHROMYCIN (OPHTHALMIC)	21.7%	ON	Yes-Generic			
GENTAMICIN OINT. (OPHTHALMIC)	0.9%	ON	Yes-Generic			
BACITRACIN/POLYMYXIN B SULFATE OINT. (OPHTHALMIC)	0.0%	OFF	No-Generic			
BLEPH-10 (OPHTHALMIC)	0.2%	ON	Yes-Generic			
CILOXAN OINTMENT (OPHTHALMIC)	0.2%	ON	Yes			
AZASITE (OPHTHALMIC)	0.1%	OFF	No			
BESIVANCE (OPHTHALMIC)	0.5%	ON	No			
NEOMYCIN/BACITRACIN/POLYMYXIN OINT (OPHTHALMIC)	0.0%	OFF	No-Generic			
ZYMAXID (OPHTHALMIC)	0.0%	OFF	No			
SULFACETAMIDE SOLUTION (OPHTHALMIC)	4.8%	ON	No-Generic			
NEOMYCIN-POLYMYXIN-GRAMICIDIN (OPHTHALMIC)	0.0%	OFF	No-Generic			
BACITRACIN (OPHTHALMIC)	0.0%	OFF	No-Generic			

LEVOFLOXACIN (OPHTHALMIC)	0.0%	OFF	No-Generic			
SULFACETAMIDE OINTMENT (OPHTHALMIC)	0.0%	ON	Yes-Generic			
NATACYN (OPHTHALMIC)	0.0%	OFF	No			

- Discussion: Catherine Decker requested clarification on a claim that may be denied. Are the preferred products listed on the EOB. Kim Wohler responded that a real-time claim response will indicate the preferred products or include special messaging.
- William Raduege made a motion to accept staff recommendations as presented.
  - Second –Ronald Diamond
  - All members were in favor of this motion.
  - Motion passes

OPHTHALMICS, ANTI-INFLAMMATORIES						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
MAXIDEX (OPHTHALMIC)	0.4%	ON	Yes			
PRED MILD (OPHTHALMIC)	0.7%	ON	Yes			
FLUOROMETHOLONE (OPHTHALMIC)	8.2%	ON	Yes-Generic			
FLAREX (OPHTHALMIC)	0.3%	ON	Yes			
FML FORTE (OPHTHALMIC)	0.4%	ON	Yes			
FLURBIPROFEN (OPHTHALMIC)	2.3%	ON	Yes-Generic			
KETOROLAC LS (OPHTHALMIC)	1.1%	OFF	Yes-Generic			
LOTEMAX DROPS (OPHTHALMIC)	8.7%	ON	Yes			
KETOROLAC (OPHTHALMIC)	0.4%	OFF	Yes-Generic			
PREDNISOLONE ACETATE (OPHTHALMIC)	57.2%	ON	Yes-Generic			
FML S.O.P. (OPHTHALMIC)	0.3%	ON	Yes			
DEXAMETHASONE (OPHTHALMIC)	1.9%	ON	Yes-Generic			
DUREZOL (OPHTHALMIC)	1.6%	OFF	Yes			
VEXOL (OPHTHALMIC)	0.2%	OFF	No			
DICLOFENAC (OPHTHALMIC)	15.7%	ON	No-Generic			
ILEVRO (OPHTHALMIC)	0.0%	NR	No			
NEVANAC (OPHTHALMIC)	0.1%	OFF	No			
PREDNISOLONE SOD PHOSPHATE (OPHTHALMIC)	0.0%	OFF	No-Generic			
OMNIPRED (OPHTHALMIC)	0.0%	ON	No-Generic			
ACUVAIL (OPHTHALMIC)	0.2%	OFF	No			
LOTEMAX GEL (OPHTHALMIC)	0.2%	NR	No			

LOTEMAX OINTMENT (OPHTHALMIC)	0.2%	OFF	No			
BROMBAY (OPHTHALMIC)Z	0.0%	OFF	No			
PROLENSA (OPHTHALMIC)	0.0%	NR	No			
BROMFENAC (OPHTHALMIC)	0.1%	OFF	No-Generic			

- Discussion: None
- Steve Maike made a motion to accept staff recommendations as presented.
  - Second –William Raduege
  - All members were in favor of this motion.
  - Motion passes

OPHTHALMICS FOR ALLERGIC CONJUNCTIVITIS						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
CROMOLYN SODIUM (OPHTHALMIC)	3.5%	ON	Yes-Generic			
KETOTIFEN OTC (OPHTHALMIC)	18.7%	ON	Yes-Generic			
ALREX (OPHTHALMIC)	1.8%	ON	Yes			
PATADAY (OPHTHALMIC)	75.0%	ON	Yes			
PATANOL (OPHTHALMIC)	0.7%	OFF	No			
EMADINE (OPHTHALMIC)	0.0%	OFF	No			
ALOMIDE (OPHTHALMIC)	0.0%	OFF	No			
LASTACAPT (OPHTHALMIC)	0.0%	OFF	No			
AZELASTINE (OPHTHALMIC)	0.1%	OFF	No-Generic			
ALOCRIAL (OPHTHALMIC)	0.0%	OFF	No			
BEPREVE (OPHTHALMIC)	0.2%	OFF	No			
EPINASTINE (OPHTHALMIC)	0.0%	OFF	No-Generic			

- Discussion: None
- Michael Witkovsky made a motion to accept staff recommendations as presented.
  - Second –William Raduege
  - All members were in favor of this motion.
  - Motion passes

OPHTHALMICS, GLAUCOMA AGENTS						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
BETIMOL (OPHTHALMIC)	0.9%	ON	Yes			
IOPIDINE (OPHTHALMIC)	0.0%	OFF	No			

AZOPT (OPHTHALMIC)	3.5%	ON	Yes			
ALPHAGAN P 0.15% (OPHTHALMIC)	4.7%	ON	Yes			
BETAXOLOL (OPHTHALMIC)	0.1%	ON	Yes-Generic			
CARTEOLOL (OPHTHALMIC)	0.2%	ON	Yes-Generic			
TRAVATAN Z 2.5 ML (OPHTHALMIC)	30.9%	ON	Yes			
BRIMONIDE (OPHTHALMIC)	4.1%	ON	Yes-Generic			
LATANOPROST 2.5ML (OPHTHALMIC)	16.5%	ON	Yes-Generic			
DORZOLAMIDE (OPHTHALMIC)	2.2%	ON	Yes-Generic			
PILOPINE HS (OPHTHALMIC)	0.0%	OFF	No			
BETOPTIC S (OPHTHALMIC)	0.8%	ON	Yes			
SIMBRINZA (OPHTHALMIC)	0.0%	NR	Yes			
TRAVATAN Z 5 ML (OPHTHALMIC)	4.7%	ON	Yes			
TIMOLOL (OPHTHALMIC)	13.5%	ON	Yes-Generic			
ISTALOL (OPHTHALMIC)	0.0%	OFF	No			
RESCULA (OPHTHALMIC)	0.0%	NR	No			
METIPRANOLOL (OPHTHALMIC)	0.1%	ON	Yes-Generic			
LEVOBUNOLOL (OPHTHALMIC)	0.8%	ON	Yes-Generic			
COMBIGAN (OPHTHALMIC)	5.6%	ON	Yes			
DORZOLAMIDE/TIMOLOL (OPHTHALMIC)	7.6%	ON	Yes-Generic			
LUMIGAN 2.5ML (OPHTHALMIC)	1.2%	OFF	No			
ALPHAGAN P 0.1% (OPHTHALMIC)	0.5%	OFF	No			
ZIOPTAN (OPHTHALMIC)	0.4%	OFF	No			
COSOPT PF (OPHTHALMIC)	0.3%	ON	Yes			
PILOCARPINE (OPHTHALMIC)	0.9%	ON	Yes-Generic			
TRAVOPROST 2.5ML (OPHTHALMIC)	0.0%	NR	No-Generic			
LUMIGAN 5ML (OPHTHALMIC)	0.3%	OFF	No			
APRACLONIDINE (OPHTHALMIC)	0.0%	OFF	No-Generic			
TIMOPTIC OCUDOSE (OPHTHALMIC)	0.1%	OFF	No			
BRIMONIDINE P 0.15% (OPHTHALMIC)	0.3%	OFF	No-Generic			
TRAVOPROST 5 ML (OPHTHALMIC)	0.0%	NR	No-Generic			

- Discussion: None
- Michael Witkovsky made a motion to accept staff recommendations as presented.
  - Second –Ronald Diamond
  - All members were in favor of this motion.
  - Motion passes



OTIC ANTIBIOTICS						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
OFLOXACIN (OTIC)	28.3%	ON	Yes-Generic			
CIPRO HC (OTIC)	0.0%	OFF	Yes			
COLY-MYCIN S (OTIC)	0.1%	ON	Yes			
NEOMYCIN/POLYMYXIN/HC SOLN/SUSP (OTIC)	36.7%	ON	Yes-Generic			
CORTISPORIN-TC (OTIC)	0.0%	OFF	No			
CIPRODEX (OTIC)	34.9%	ON	Yes			

- Discussion: None
- William Raduege made a motion to accept staff recommendations as presented.
  - Second –Catherine Decker
  - All members were in favor of this motion.
  - Motion passes

OTIC ANTI-INFECTIVES & ANESTHETICS						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
ANTIPYRINE / BENZOCAINE (OTIC)	94.2%	ON	Yes-Generic			
ACETIC ACID (OTIC)	5.3%	ON	Yes-Generic			
ACETIC ACID/ALUMINUM (OTIC)	0.1%	OFF	No-Generic			
PINNACAINE (OTIC)	0.0%	OFF	No-Generic			
OTIC CARE (OTIC)	0.0%	NR	No			
OTOZIN (OTIC)	0.0%	OFF	No-Generic			
MYOXIN (OTIC)	0.0%	OFF	No-Generic			
ACETIC ACID HC (OTIC)	0.4%	OFF	No-Generic			

- Discussion: None
- Michael Witkovsky made a motion to accept staff recommendations as presented.
  - Second –Pat Towers
  - All members were in favor of this motion.
  - Motion passes

ANTIPSORIATICS, TOPICAL						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
DOVONEX CREAM (TOPICAL)	38.0%	ON	Yes			
VECTICAL (TOPICAL)	0.8%	OFF	Yes			

TACLONEX SCALP (TOPICAL)	2.0%	OFF	Yes			
TACLONEX OINTMENT (TOPICAL)	5.0%	OFF	Yes			
CALCIPOTRIENE SOLUTION (TOPICAL)	11.5%	ON	Yes-Generic			
CALCITRENE (TOPICAL)	0.8%	OFF	Yes-Generic			
SORILUX (TOPICAL)	0.0%	NR	No			
CALCIPOTRIENE CREAM (TOPICAL)	1.1%	OFF	No-Generic			
CALCIPOTRIENE OINTMENT (TOPICAL)	40.5%	ON	No-Generic			
CALCITRIOL OINTMENT (TOPICAL)	0.3%	OFF	No-Generic			

- Discussion: None
- Ronald Diamond made a motion to accept staff recommendations as presented.
  - Second –Alicia Walker
  - All members were in favor of this motion.
  - Motion passes

IMMUNOMODULATORS, ATOPIC DERMATITIS						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
ELIDEL (TOPICAL)	53.4%	OFF	Yes			
PROTOPIC (TOPICAL)	46.6%	OFF	No			

- Discussion: None
- William Raduege made a motion to accept staff recommendations as presented.
  - Second –Steve Maike
  - All members in favor of this motion.
  - Motion passes

STEROIDS, TOPICAL LOW						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
HYDROCORTISONE CREAM OTC (TOPICAL)	6.0%	ON	Yes-Generic			
SCALPICIN OTC (TOPICAL)	0.0%	ON	Yes-Generic			
HYDROCORTISONE CREAM (TOPICAL)	38.4%	ON	Yes-Generic			
HYDROCORTISONE LOTION OTC (TOPICAL)	0.8%	ON	Yes-Generic			
HYDROCORTISONE OINTMENT OTC (TOPICAL)	1.1%	ON	Yes-Generic			
HYDROCORTISONE / MIN OIL / PET OINT. (TOPICAL)	0.0%	ON	Yes-Generic			

HYDROCORTISONE OINTMENT (TOPICAL)	30.9%	ON	Yes-Generic			
ALCLOMETASONE DIPROPIONATE CREAM (TOPICAL)	0.0%	OFF	Yes-Generic			
HYDROCORTISONE/ALOE GEL (TOPICAL)	0.0%	OFF	No-Generic			
DERMA-SMOOTHIE-FS (TOPICAL)	0.1%	OFF	No			
FLUOCINOLONE 0.01% OIL (TOPICAL)	1.8%	ON	Yes-Generic			
ALCLOMETASONE DIPROPIONATE OINT. (TOPICAL)	0.0%	OFF	Yes-Generic			
HYDROCORTISONE LOTION (TOPICAL)	2.0%	ON	Yes-Generic			
TEXACORT (TOPICAL)	0.0%	OFF	No-Generic			
HYDROCORTISONE ACETATE/UREA (TOPICAL)	0.0%	OFF	No-Generic			
CAPEX SHAMPOO (TOPICAL)	0.0%	OFF	No			
DESONIDE OINTMENT (TOPICAL)	9.9%	ON	No-Generic			
DESONATE GEL (TOPICAL)	0.0%	OFF	No			
VERDESO (TOPICAL)	0.0%	OFF	No			
DESONIDE LOTION (TOPICAL)	0.1%	OFF	No-Generic			
DESONIDE CREAM (TOPICAL)	9.0%	ON	No-Generic			

- Discussion: Alicia Walker asked what the benefit is for taking off the desonide product. Rick Pope responded that there are other products that are less expensive to the state.
- Pat Towers made a motion to accept staff recommendations as presented.
  - Second –William Raduege
  - The vote was 8-1 in favor of the motion. Alicia Walker was opposed to the motion.
  - Motion passes

STERIODS, TOPICAL MEDIUM						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
HYDROCORTISONE BUTYRATE SOLUTION BRAND (TOPICAL)	0.2%	ON	No-Generic			
MOMETASONE FUROATE SOLUTION (TOPICAL)	0.3%	OFF	Yes-Generic			
PANDEL (TOPICAL)	0.0%	OFF	No			
MOMETASONE FUROATE CREAM (TOPICAL)	0.9%	OFF	Yes-Generic			
FLUTICASONE PROPIONATE CREAM (TOPICAL)	39.6%	ON	Yes-Generic			
HYDROCORTISONE BUTYRATE SOLUTION (TOPICAL)	0.7%	ON	No-Generic			
HYDROCORTISONE VALERATE CREAM	19.9%	ON	Yes-Generic			

(TOPICAL)						
FLUTICASONE PROPIONATE OINTMENT (TOPICAL)	16.4%	ON	Yes-Generic			
MOMETASONE FUROATE OINTMENT (TOPICAL)	0.6%	OFF	Yes-Generic			
DERMATOP OINTMENT (TOPICAL)	0.0%	OFF	No			
CLODERM (TOPICAL)	0.0%	OFF	No			
HYDROCORTISONE BUTYRATE OINTMENT BRAND (TOPICAL)	0.2%	ON	No-Generic			
PREDNICARBATE CREAM (TOPICAL)	0.0%	OFF	No-Generic			
FLUOCINOLONE ACETONIDE CREAM (TOPICAL)	0.1%	OFF	No-Generic			
SYNALAR OINTMENT (TOPICAL)	0.0%	OFF	No			
SYNALAR CREAM (TOPICAL)	0.0%	OFF	No			
PREDNICARBATE OINTMENT (TOPICAL)	0.0%	OFF	No-Generic			
LUXIQ (TOPICAL)	0.1%	OFF	No			
HYDROCORTISONE BUTYRATE CREAM (TOPICAL)	1.2%	ON	No-Generic			
HYDROCORTISONE BUTYRATE CREAM BRAND (TOPICAL)	0.3%	ON	No-Generic			
HYDROCORTISONE BUTYRATE OINTMENT (TOPICAL)	0.5%	ON	No-Generic			
FLUOCINOLONE ACETONIDE OINTMENT (TOPICAL)	0.6%	OFF	No-Generic			
SYNALAR SOLUTION (TOPICAL)	0.0%	OFF	No			
FLUOCINOLONE ACETONIDE SOLUTION (TOPICAL)	1.0%	OFF	No-Generic			
CUTIVATE LOTION (TOPICAL)	0.0%	OFF	No			
HYDROCORTISONE VALERATE OINTMENT (TOPICAL)	12.8%	ON	Yes-Generic			
CORDRAN TAPE (TOPICAL)	0.2%	OFF	No			
BETAMETHASONE VALERATE FOAM (TOPICAL)	4.3%	NR	No-Generic			
FLUTICASONE PROPIONATE LOTION (TOPICAL)	0.0%	OFF	No-Generic			

- Discussion: None

- Michael Witkovsky made a motion to accept staff recommendations as presented.
  - Second –Lawrence Fleming
  - All members were in favor of this motion.
  - Motion passes

STEROIDS, TOPICAL HIGH						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
BETAMET DIPROP/PROP GLY CREAM (TOPICAL)	0.8%	ON	Yes-Generic			
TRIAMCINOLONE ACETONIDE CREAM (TOPICAL)	49.7%	ON	Yes-Generic			
BETAMETHASONE VALERATE CREAM (TOPICAL)	1.8%	ON	Yes-Generic			
TRIAMCINOLONE ACETONIDE OINTMENT (TOPICAL)	29.7%	ON	Yes-Generic			
FLUOCINONIDE EMOLLIENT (TOPICAL)	0.5%	ON	Yes-Generic			
TRIAMCINOLONE ACETONIDE LOTION (TOPICAL)	0.1%	OFF	No-Generic			
BETAMETHASONE VALERATE OINTMENT (TOPICAL)	1.6%	ON	Yes-Generic			
KENALOG AEROSOL (TOPICAL)	0.0%	OFF	No			
BETAMETHASONE DIPROPIONATE LOTION (TOPICAL)	1.0%	ON	Yes-Generic			
HALOG OINTMENT (TOPICAL)	0.0%	OFF	No			
FLUOCINONIDE OINTMENT (TOPICAL)	4.2%	ON	Yes-Generic			
FLUOCINONIDE CREAM (TOPICAL)	2.9%	ON	Yes-Generic			
VANOS (TOPICAL)	0.0%	OFF	No			
BETAMETHASONE VALERATE LOTION (TOPICAL)	0.6%	ON	Yes-Generic			
FLUOCINONIDE GEL (TOPICAL)	0.3%	ON	Yes-Generic			
BETAMETHASONE DIPROPIONATE CREAM (TOPICAL)	3.1%	ON	Yes-Generic			
FLUOCINONIDE SOLUTION (TOPICAL)	1.8%	ON	Yes-Generic			
BETAMETHASONE DIPROPIONATE GEL (TOPICAL)	0.0%	ON	Yes-Generic			
BETAMETHASONE DIPROPIONATE OINTMENT (TOPICAL)	1.2%	ON	Yes-Generic			
BETAMET DIPROP / PROP GLY LOTION (TOPICAL)	0.1%	ON	Yes-Generic			
BETAMET DIPROP / PROP GLY OINTMENT (TOPICAL)	0.4%	ON	Yes-Generic			

DIFLORASONE DIACETATE OINTMENT (TOPICAL)	0.0%	OFF	No-Generic			
HALOG CREAM (TOPICAL)	0.0%	OFF	No			
TOPICORT OINTMENT (TOPICAL)	0.0%	OFF	No			
TRIANEX OINTMENT (TOPICAL)	0.1%	OFF	No-Generic			
DESOXIMETASONE GEL (TOPICAL)	0.0%	OFF	No-Generic			
DIFLORASONE DIACETATE CREAM (TOPICAL)	0.0%	OFF	No-Generic			
DESOXIMETASONE CREAM (TOPICAL)	0.1%	OFF	No-Generic			
AMCINONIDE CREAM (TOPICAL)	0.0%	OFF	No-Generic			
AMCINONIDE LOTION (TOPICAL)	0.0%	OFF	No-Generic			
AMCINONIDE OINTMENT (TOPICAL)	0.0%	OFF	No-Generic			
TOPICORT SPRAY (TOPICAL)	0.0%	OFF	No			
DESOXIMETASONE OINTMENT (TOPICAL)	0.1%	OFF	No-Generic			

- Discussion: None
- Michael Witkovsky made a motion to accept staff recommendations as presented.
  - Second –William Raduege
  - All members were in favor of this motion.
  - Motion passes

STEROIDS, TOPICAL VERY HIGH						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
CLOBETASOL PROPIONATE CREAM (TOPICAL)	28.8%	ON	Yes-Generic			
CLOBETASOL PROPIONATE SOLUTION (TOPICAL)	19.2%	ON	Yes-Generic			
CLOBETASOL PROPIONATE OINTMENT (TOPICAL)	42.4%	ON	Yes-Generic			
CLOBETASOL PROPIONATE GEL (TOPICAL)	1.9%	ON	Yes-Generic			
CLOBETASOL EMOLLIENT (TOPICAL)	2.3%	ON	Yes-Generic			
CLOBEX SHAMPOO (TOPICAL)	0.1%	OFF	Yes			
CLOBEX LOTION (TOPICAL)	0.0%	OFF	Yes			
HALOBETASOL PROPIONATE CREAM (TOPICAL)	1.5%	ON	No-Generic			
CLOBEX SPRAY (TOPICAL)	0.2%	OFF	No			
HALOBETASOL PROPIONATE OINTMENT	2.5%	ON	No-Generic			

(TOPICAL)						
CLOBETASOL PROPIONATE FOAM (TOPICAL)	0.5%	OFF	No-Generic			
APEXICON E (TOPICAL)	0.2%	OFF	No-Generic			
CLOBETASOL LOTION (TOPICAL)	0.0%	OFF	No-Generic			
OLUX-E (TOPICAL)	0.0%	OFF	No			
CLOBETASOL SHAMPOO (TOPICAL)	0.4%	OFF	No-Generic			

- Discussion: None
- Alicia Walker made a motion to accept staff recommendations as presented.
  - Second –William Raduege
  - All members were in favor of this motion.
  - Motion passes

<b>CYTOKINE AND CAM ANTAGONISTS</b>						
<b>Brand Name</b>	<b>Current Market Share</b>	<b>Current PDL Status</b>	<b>PDL Recommendation</b>	<b>COMMITTEE RECOMMENDATIONS</b>	<b>STATE MODIFICATIONS</b>	<b>SECRETARY MODIFICATIONS</b>
ENBREL KIT (INJECTION)	1.6%	ON	Yes			
KINERET (INJECTION)	0.6%	OFF	No			
ENBREL PEN (INJECTION)	23.8%	ON	Yes			
ENBREL SYRINGE (INJECTION)	8.5%	ON	Yes			
SIMPONI PEN INJECTER (INJECTION)	0.5%	OFF	No			
CIMZIA SYRINGE KIT (INJECTION)	6.7%	ON	Yes			
HUMIRA KIT (INJECTION)	9.7%	ON	Yes			
HUMIRA PEN KIT (INJECTION)	45.2%	ON	Yes			
SIMPONI SYRINGE (INJECTION)	0.3%	OFF	No			
CIMZIA KIT (INJECTION)	0.9%	ON	Yes			
ORENCIA SYRINGE (SUBCUT.)	2.1%	OFF	No			
XELJANZ (ORAL)	0.1%	NR	No			
STELARA SYRINGE (INJECTION)	0.0%	NR	No			

- Discussion: Rachel Currans-Henry noted that this class has clinical PA for all agents.
- Pat Towers made a motion to accept staff recommendations as presented.
  - Second –William Raduege
  - All members were in favor of this motion.
  - Motion passes

NSAIDS						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
IBUPROFEN TABLET OTC (ORAL)	1.2%	ON	Yes-Generic			
MOBIC SUSPENSION (ORAL)	0.0%	OFF	No			
MELOXICAM TABLET (ORAL)	12.4%	ON	Yes-Generic			
IBUPROFEN TABLET (ORAL)	33.8%	ON	Yes-Generic			
NAPROXEN SODIUM OTC (ORAL)	0.4%	ON	Yes-Generic			
INDOCIN SUSPENSION (ORAL)	0.0%	OFF	No			
NAPROXEN TABLET (ORAL)	16.4%	ON	Yes-Generic			
NAPROXEN SODIUM (ORAL)	1.3%	ON	Yes-Generic			
IBUPROFEN TAB CHEW OTC (ORAL)	0.0%	ON	Yes-Generic			
KETOROLAC (ORAL)	1.9%	ON	Yes-Generic			
IBUPROFEN SUSPENSION OTC (ORAL)	0.9%	ON	Yes-Generic			
IBUPROFEN SUSPENSION (ORAL)	8.9%	ON	Yes-Generic			
IBUPROFEN DROPS SUSPENSION OTC (ORAL)	0.0%	ON	Yes-Generic			
DICLOFENAC POTASSIUM (ORAL)	0.8%	ON	Yes-Generic			
IBUPROFEN CAPSULE OTC (ORAL)	0.0%	ON	Yes-Generic			
INDOMETHACIN CAPSULE (ORAL)	2.1%	ON	Yes-Generic			
NAPROXEN EC (ORAL)	0.6%	ON	Yes-Generic			
SULINDAC (ORAL)	0.4%	ON	Yes-Generic			
PONSTEL (ORAL)	0.0%	OFF	No			
NAPROSYN SUSPENSION (ORAL)	0.0%	ON	Yes			
FLURBIPROFEN (ORAL)	0.1%	ON	Yes-Generic			
KETOPROFEN (ORAL)	0.3%	ON	Yes-Generic			
DICLOFENAC SR (ORAL)	0.2%	ON	Yes-Generic			
ETODOLAC (ORAL)	1.1%	ON	Yes-Generic			
VOLTAREN (ORAL)	4.6%	ON	Yes			
NAPROXEN SUSPENSION (TOPICAL)	0.2%	ON	Yes-Generic			
NABUMETONE (ORAL)	0.3%	OFF	Yes			
DICLOFENAC SODIUM (ORAL)	8.2%	ON	Yes-Generic			
VIMOVO (ORAL)	0.0%	OFF	No			



ETODOLAC TAB SR (ORAL)	0.0%	OFF	No-Generic			
DUEXIS (ORAL)	0.0%	OFF	No			
MELOXICAM SUSPENSION (ORAL)	0.0%	OFF	No-Generic			
NALFON (ORAL)	0.0%	OFF	No			
CELEBREX (ORAL)	2.4%	OFF	No			
NAPRELAN (TOPICAL)	0.0%	OFF	No			
TOLMETIN SODIUM CAPSULE (ORAL)	0.0%	OFF	No-Generic			
PENNSAID (TOPICAL)	0.0%	OFF	No			
TOLMETIN SODIUM TABLET (ORAL)	0.0%	OFF	No-Generic			
PIROXICAM (ORAL)	1.0%	ON	Yes-Generic			
SPRIX (ORAL)	0.0%	OFF	No			
FENOPROFEN (ORAL)	0.0%	OFF	No-Generic			
DICLOFENAC SODIUM/MISOPROSTOL (ORAL)	0.0%	NR	No-Generic			
INDOMETHACIN CAPSULE ER (ORAL)	0.0%	OFF	No-Generic			
FLECTOR (TOPICAL)	0.1%	OFF	No			
OXAPROZIN (ORAL)	0.1%	ON	No-Generic			
ARTHROTEC (ORAL)	0.0%	OFF	No			
MECLOFENAMATE (ORAL)	0.0%	OFF	No-Generic			
DIFLUNISAL (ORAL)	0.0%	OFF	No-Generic			
ZIPSOR (ORAL)	0.0%	OFF	No			
INDOCIN (RECTAL)	0.0%	ON	Yes-Generic			
MEFENAMIC ACID (ORAL)	0.0%	OFF	No-Generic			
KETOPROFEN ER (ORAL)	0.0%	OFF	No-Generic			

- Alicia Walker made a motion to accept staff recommendations and keep nabumetone as non-preferred.
  - Second –Michael Witkovsky
  - Lawrence Fleming asked Alicia Walker what her reasoning was to leave nabumetone as non-preferred. Alicia Walker responded that due to low utilization, it doesn't seem to make sense to add the drug. It is more costly than the other preferred agents. Rick Pope responded that he believes it is cost neutral to add nabumetone. Alicia Walker withdrew her motion.
  - Motion withdrawn.
  
- James Boblin made a motion to accept staff recommendations as presented.
  - Second –Ronald Diamond
  - All members were in favor of this motion.
  - Motion passes

NEUROPATHIC PAIN						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
GABAPENTIN CAPSULE (ORAL)	43.6%	ON	Yes-Generic			
CAPSAICIN OTC (TOPICAL)	0.3%	ON	Yes-Generic			
GABAPENTIN TABLET (ORAL)	14.7%	ON	Yes-Generic			
GRALISE (ORAL)	0.0%	OFF	No			
SAVELLA DOSE PACK (ORAL)	0.1%	ON	Yes			
SAVELLA (ORAL)	2.2%	ON	Yes			
LIDODERM (ORAL)	2.7%	OFF	Yes			
LYRICA SOLUTION (ORAL)	0.0%	ON	Yes			
GABAPENTIN SOLUTION (ORAL)	0.6%	ON	Yes-Generic			
LYRICA CAPSULE (ORAL)	17.5%	ON	Yes			
CYMBALTA (ORAL)	18.3%	ON	Yes			
HORIZANT (ORAL)	0.0%	OFF	No			

- Discussion: Rachel Currans-Henry noted that when generic Cymbalta becomes available brand medically necessary policy will be evaluated. If applied, there will be no grandfathering for Cymbalta.
- James Boblin made a motion to accept staff recommendations as presented.
  - Second –Ronald Diamond
  - The vote was 8-1 in favor of the motion. Alicia Walker was opposed to the motion.
  - Motion passes

ALZHEIMER'S AGENTS						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
DONEPEZIL TABLET (ORAL)	53.0%	ON	Yes-Generic			
NAMENDA TABLET DOSE PACK (ORAL)	0.2%	ON	Yes			
EXELON (TRANSDERM)	5.9%	ON	Yes			
GALANTAMINE ER (ORAL)	1.1%	OFF	No-Generic			
NAMENDA TABLET (ORAL)	35.7%	ON	Yes			
GALANTAMINE TABLET (ORAL)	1.2%	OFF	No-Generic			
EXELON CAPSULES (ORAL)	1.4%	ON	Yes			
RIVASTIGMINE CAPSULES (ORAL)	0.4%	OFF	No-Generic			
NAMENDA SOLUTION	0.2%	ON	Yes			

(ORAL)						
ARICEPT 23 MG (ORAL)	0.6%	OFF	No			
DONEPEZIL ODT (ORAL)	0.2%	ON	Yes-Generic			
NAMENDA XR (ORAL)	0.0%	NR	No			
RAZADYNE SOLUTION (ORAL)	0.0%	NR	No			
DONEPEZIL 23 MG (ORAL)	0.0%	NR	No-Generic			
EXELON SOLUTION (ORAL)	0.0%	OFF	No			
GALANTAMINE SOLUTION (ORAL)	0.0%	OFF	No-Generic			

- Discussion: None
- Ronald Diamond made a motion to accept staff recommendations as presented.
  - Second –James Boblin
  - All members were in favor of this motion.
  - Motion passes

ANTICONVULSANTS						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
CLONAZEPAM (ORAL)	25.1%	ON	Yes-Generic			
CARBAMAZEPINE TABLET (ORAL)	2.4%	ON	Yes-Generic			
TOPIRAMATE TABLETS (ORAL)	12.2%	ON	Yes-Generic			
PRIMIDONE (ORAL)	1.0%	ON	Yes-Generic			
LAMOTRIGINE TABLET (ORAL)	18.7%	ON	Yes-Generic			
ZONISAMIDE (ORAL)	1.5%	ON	Yes-Generic			
TEGRETOL XR (ORAL)	0.6%	ON	Yes			
VALPROATE SYRUP (ORAL)	1.1%	ON	Yes-Generic			
CELONTIN (ORAL)	0.0%	ON	Yes			
CARBAMAZEPINE CHEWABLE TABLET (ORAL)	0.6%	ON	Yes-Generic			
PHENOBARBITAL TABLET (ORAL)	1.6%	ON	Yes-Generic			
PHENYTOIN CAPSULE (ORAL)	1.2%	ON	Yes-Generic			
LEVETIRACETAM TABLETS (ORAL)	6.3%	ON	Yes-Generic			
VALPROIC ACID (ORAL)	0.2%	ON	Yes-Generic			
OXCARBAZEPINE TABLETS (ORAL)	2.7%	ON	Yes-Generic			
GABITRIL (ORAL)	0.1%	ON	Yes			
DIVALPROEX TABLET (ORAL)	4.7%	ON	Yes-Generic			
PHENYTOIN EXT CAPSULE (GENERIC PHENYTEK) (ORAL)	0.1%	ON	Yes-Generic			
DEPAKOTE SPRINKLE (ORAL)	1.5%	ON	Yes			

PHENYTOIN SUSPENSION (ORAL)	0.1%	ON	Yes-Generic			
LEVETIRACETAM SOLUTION (ORAL)	2.4%	ON	Yes-Generic			
PEGANONE (ORAL)	0.0%	ON	Yes			
PHENYTOIN CHEWABLE TABLET (ORAL)	0.1%	NR	Yes-Generic			
LEVETIRACETAM ER (ORAL)	0.4%	ON	Yes-Generic			
CLONAZEPAM ODT (ORAL)	0.2%	OFF	No-Generic			
CARBATROL (ORAL)	0.7%	ON	Yes			
LAMICTAL TABLET DOSE PACK (ORAL)	0.1%	ON	Yes			
EQUETRO (ORAL)	0.0%	OFF	No			
STAVZOR (ORAL)	0.0%	OFF	No			
DILANTIN INFATAB (ORAL)	0.1%	ON	Yes-Generic			
FELBATOL TABLET (ORAL)	0.3%	ON	Yes			
TOPIRAMATE SPRINKLE (ORAL)	0.4%	ON	Yes-Generic			
PHENOBARBITAL ELIXIR (ORAL)	0.6%	ON	Yes-Generic			
DIASTAT (RECTAL)	0.0%	ON	Yes			
ETHOSUXIMIDE CAPSULE (ORAL)	0.2%	ON	Yes-Generic			
TRILEPTAL SUSPENSION (ORAL)	0.2%	ON	Yes			
DIVALPROEX ER (ORAL)	7.4%	ON	Yes-Generic			
CARBAMAZEPINE XR (ORAL)	0.1%	OFF	No-Generic			
ETHOSUXIMIDE SYRUP (ORAL)	0.2%	ON	Yes-Generic			
CARBAMAZEPINE SUSPENSION (ORAL)	0.2%	ON	Yes-Generic			
CARBAMAZEPINE ER (GENERIC CARBATROL) (ORAL)	0.5%	ON	Yes-Generic			
DIVALPROEX SPRINKLE (ORAL)	0.2%	OFF	No-Generic			
FELBATOL SUSPENSION (ORAL)	0.3%	ON	Yes			
LAMOTRIGINE TABLET DOSE PACK (ORAL)	0.0%	ON	Yes-Generic			
DIASTAT ACUDIAL (RECTAL)	0.5%	ON	Yes			
LAMICTAL ODT DOST PACK (ORAL)	0.0%	OFF	No			
PHENYTEK (ORAL)	0.0%	OFF	No-Generic			
OXCARBAZEPINE SUSPENSION (ORAL)	0.3%	ON	Yes-Generic			
TROKENDI XR (ORAL)	0.0%	NR	No			
DIAZEPAM DEVICE (RECTAL)	0.0%	OFF	No-Generic			
VIMPAT SOLUTION (ORAL)	0.1%	OFF	No			
DIAZEPAM (RECTAL)	0.0%	OFF	No-Generic			
ONFI TABLET (ORAL)	0.4%	OFF	No			
VIMPAT TABLET (ORAL)	0.8%	OFF	No			
OXTELLAR XR (ORAL)	0.0%	NR	No			

ONFI SUSPENSION (ORAL)	0.0%	OFF	No			
LAMICTAL ODT (ORAL)	0.2%	OFF	No			
TIAGABINE (ORAL)	0.0%	NR	No-Generic			
LAMICTAL XR DOSE PACK (ORAL)	0.1%	OFF	No			
POTIGA (ORAL)	0.1%	OFF	No			
BANZEL TABLET (ORAL)	0.2%	OFF	No			
LAMOTRIGINE XR (ORAL)	0.3%	NR	No-Generic			
LAMICTAL XR (ORAL)	0.3%	OFF	No			
FELBAMATE TABLET (ORAL)	0.1%	OFF	No-Generic			
FELBAMATE SUSPENSION (ORAL)	0.0%	OFF	No-Generic			
BANZEL SUSPENSION (ORAL)	0.0%	OFF	No			
SABRIL POWDER PACK (ORAL)	0.0%	OFF	No			
SABRIL TABLET (ORAL)	0.0%	OFF	No			

- Discussion: None
- William Raduege made a motion to accept staff recommendations as presented.
  - Second –Pat Towers
  - All members were in favor of this motion.
  - Motion passes

ANTIDEPRESSANTS, OTHER						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
VENLAFAXINE ER TABLETS (UPSTATE) (ORAL)	0.00%	OFF	No-Generic			
TRAZODONE (ORAL)	27.9%	ON	Yes-Generic			
MIRTAZAPINE TABLET (ORAL)	12.1%	ON	Yes-Generic			
VENLAFAXINE ER CAPSULES (ORAL)	22.4%	ON	Yes-Generic			
BUPROPION SR (ORAL)	13.0%	ON	Yes-Generic			
MARPLAN (ORAL)	0.0%	ON	Yes			
VENLAFAXINE (ORAL)	3.3%	ON	Yes-Generic			
NEFAZODONE (ORAL)	0.1%	OFF	No-Generic			
BUPROPION (ORAL)	1.8%	ON	Yes-Generic			
BUPROPRION XL (ORAL)	16.2%	ON	Yes-Generic			
MIRTAZAPINE ODT (ORAL)	0.3%	ON	Yes-Generic			
PHENELZINE (ORAL)	0.0%	ON	Yes-Generic			
PRISTIQ (ORAL)	1.4%	OFF	No			
DESVENLAFAXINE ER (ORAL)	0.0%	NR	No-Generic			
VIIIBRYD DOSE PACK (ORAL)	0.0%	OFF	No			

VIIIBRYD (ORAL)	1.3%	OFF	No			
NARDIL (ORAL)	0.0%	ON	Yes			
OLEPTRO ER (ORAL)	0.0%	OFF	No			
FORFIVO XL (ORAL)	0.0%	NR	No			
VENLAFAXINE ER TABLETS (GENERIC) (ORAL)	0.0%	OFF	No-Generic			
VENLAFAXINE ER TABLETS (SCHWARZ) (ORAL)	0.1%	OFF	No-Generic			
TRANLYCYPROMINE SULFATE (ORAL)	0.0%	ON	Yes-Generic			
APLENZIN (ORAL)	0.0%	OFF	No			
EMSAM (TRANSDERMAL)	0.0%	OFF	No			

- Discussion: None
- William Raduege made a motion to accept staff recommendations as presented.
  - Second –Lawrence Fleming
  - All members were in favor of this motion.
  - Motion passes

ANTIDEPRESSANTS, SSRIs						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
FLUOXETINE 60 MG (ORAL)	0.1%	ON	Yes-Generic			
FLUOXETINE TABLET (ORAL)	3.6%	ON	Yes-Generic			
CITALOPRAM TABLET (ORAL)	24.7%	ON	Yes-Generic			
SERTRALINE TABLET (ORAL)	31.4%	ON	Yes-Generic			
ESCITALOPRAM TABLET (ORAL)	5.4%	ON	Yes-Generic			
FLUOXETINE CAPSULE (ORAL)	22.4%	ON	Yes-Generic			
FLUOXETINE SOLUTION (ORAL)	0.5%	ON	Yes-Generic			
PAROXETINE TABLET (ORAL)	10.4%	ON	Yes-Generic			
FLUVOXAMINE (ORAL)	0.8%	ON	Yes-Generic			
PEXEVA (ORAL)	0.0%	OFF	No			
CITALOPRAM SOLUTION (ORAL)	0.1%	ON	Yes-Generic			
LUVOX CR (ORAL)	0.0%	OFF	No			
SERTRALINE CONC (ORAL)	0.2%	ON	Yes-Generic			
BRISDELLE (ORAL)	0.0%	NR	No			
PAROXETINE CR (ORAL)	0.2%	OFF	No-Generic			
PAXIL SUSPENSION (ORAL)	0.0%	ON	Yes			

FLUOXETINE CAPSULE DR (ORAL)	0.0%	OFF	No-Generic			
FLUVOXAMINE ER (ORAL)	0.0%	NR	No-Generic			
ESCITALOPRAM SOUTION (ORAL)	0.0%	ON	Yes-Generic			

- Discussion: None
- Michael Witkovsky made a motion to accept staff recommendations as presented.
  - Second –Pat Towers
  - All members were in favor of this motion.
  - Motion passes

ANTIPARKINSON'S AGENTS						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
BENZTROPINE (ORAL)	34.2%	ON	Yes-Generic			
ROPINIROLE (ORAL)	28.6%	ON	Yes-Generic			
PRAMIPEXOLE (ORAL)	12.6%	ON	Yes-Generic			
ZELAPAR (ORAL)	0.0%	OFF	No			
TRIHXYPHENIDYL TABLET (ORAL)	5.1%	ON	Yes-Generic			
CARBIDOPA/ LEVODOPA (ORAL)	13.6%	ON	Yes-Generic			
TRIHXYPHENIDYL ELIXIR (ORAL)	0.3%	ON	Yes-Generic			
LODOSYN (ORAL)	0.2%	NR	Yes			
CARBIDOPA/ LEVODOPA ER (ORAL)	2.7%	ON	Yes-Generic			
SELEGILINE TABLET (ORAL)	0.1%	ON	Yes-Generic			
TASMAR (ORAL)	0.0%	OFF	No			
CARBIDOPA/LEVODOPA ODT (ORAL)	0.2%	ON	Yes-Generic			
SELEGILINE CAPSULE (ORAL)	0.2%	ON	Yes-Generic			
BROMOCRIPTINE (ORAL)	0.9%	ON	Yes-Generic			
AZILECT (ORAL)	0.3%	OFF	No			
NEUPRO (TRANSDERM)	0.2%	OFF	No			
REQUIP XL (ORAL)	0.1%	OFF	No			
ENTACAPONE (ORAL)	0.2%	OFF	No-Generic			
COMTAN (ORAL)	0.1%	OFF	No			
STALEVO (ORAL)	0.4%	ON	Yes			
MIRAPEX ER (ORAL)	0.0%	OFF	No			
ROPINIROLE ER (ORAL)	0.2%	OFF	No-Generic			
CARBIDOPA/LEVODOPA/	0.0%	OFF	No-Generic			

ENTACAPONE (ORAL)						
PARCOPA (ORAL)	0.0%	OFF	No-Generic			

- Discussion: None
- James Boblin made a motion to accept staff recommendations as presented.
  - Second –William Raduege
  - All members were in favor of this motion.
  - Motion passes

ANTIPSYCHOTICS						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
RISPERIDONE TABLET (ORAL)	26.7%	ON	Yes-Generic			
FLUPHENAZINE TABLET (ORAL)	0.9%	ON	Yes-Generic			
QUETIAPINE TABLETS (ORAL)	26.5%	ON	Yes-Generic			
OLANZAPINE TABLET (ORAL)	6.9%	ON	Yes-Generic			
HALOPERIDOL (ORAL)	3.6%	ON	Yes-Generic			
THIOTHIXENE (ORAL)	0.4%	ON	Yes-Generic			
THIORIDAZINE (ORAL)	0.2%	OFF	No-Generic			
ORAP (ORAL)	0.1%	ON	Yes			
TRIFLUOPERAZINE (ORAL)	0.2%	ON	Yes-Generic			
LOXAPINE (ORAL)	0.4%	ON	Yes-Generic			
AMITRIPTYLINE/PERPHENAZINE (ORAL)	0.1%	ON	Yes-Generic			
HALOPERIDOL LACTATE CONC (ORAL)	0.1%	ON	Yes-Generic			
RISPERIDONE SOLUTION (ORAL)	0.9%	ON	Yes-Generic			
FLUPHENAZINE ELIXIR/SOLN (ORAL)	0.0%	ON	Yes-Generic			
PERPHENAZINE (ORAL)	0.3%	ON	Yes-Generic			
FANAPT TITRATION PACK (ORAL)	0.0%	OFF	No			
LATUDA (ORAL)	1.1%	OFF	Yes			
CHLORPROMAZINE (ORAL)	0.6%	ON	Yes-Generic			
CLOZAPINE (ORAL)	3.0%	ON	Yes-Generic			
OLANZAPINE ODT (SUBLINGUAL)	0.6%	OFF	No-Generic			
CLOZAPINE ODT (ORAL)	0.1%	OFF	No-Generic			
FANAPT TABLET (ORAL)	0.2%	OFF	No			
SEROQUEL XR (ORAL)	1.3%	ON	No			
RISPERIDONE ODT (ORAL)	0.9%	ON	Yes-Generic			
ZIPRASIDONE CAPSULE (ORAL)	7.9%	ON	Yes-Generic			
SAPHRIS (SUBLINGUAL)	0.5%	OFF	No			



ABILIFY TABLET (ORAL)	15.0%	OFF	No			
SYMBYAX (ORAL)	0.0%	OFF	No			
FAZACLO (ORAL)	0.1%	OFF	No			
ABILIFY DISCMELT (ORAL)	0.1%	OFF	No			
INVEGA (ORAL)	1.2%	OFF	No			
OLANZAPINE/FLUOXETINE (ORAL)	0.0%	OFF	No-Generic			
ABILIFY SOLUTION (ORAL)	0.1%	OFF	No			

- Discussion: Catherine Decker asked DHS to confirm that injectable formulations were not being reviewed. Staff confirmed that injectable formulations are not included in the PDL class.
- Rachel Currans-Henry stated that DHS plans to look at claims data to analyze non-preferred drugs prescribed upon hospital discharge.
- Ronald Diamond made a motion to accept staff recommendations as presented.
  - Second –Lawrence Fleming
  - All members were in favor of this motion.
  - Motion passes

SEDATIVE HYPNOTICS						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
ZOLPIDEM (ORAL)	75.7%	ON	Yes-Generic			
TEMAZEPAM (ORAL)	13.5%	ON	Yes-Generic			
CHLORAL HYDRATE SYRUP (ORAL)	0.0%	ON	Yes-Generic			
FLURAZEPAM (ORAL)	0.2%	OFF	No-Generic			
TRIAZOLAM (ORAL)	0.3%	OFF	Yes-Generic			
ZALEPLON (ORAL)	2.0%	ON	Yes-Generic			
SOMNOTE (ORAL)	0.0%	OFF	No-Generic			
ESTAZOLAM (ORAL)	0.5%	ON	Yes-Generic			
ZOLPIMIST (ORAL)	0.0%	OFF	No			
INTERMEZZO (SUBLINGUAL)	0.0%	OFF	No			
ROZEREM (ORAL)	1.5%	ON	Yes			
DORAL (ORAL)	0.0%	OFF	No			
EDLUAR (SUBLINGUAL)	0.0%	OFF	No			
LUNESTA (ORAL)	3.1%	OFF	No			
SILENOR (ORAL)	0.0%	OFF	No			
ZOLPIDEM ER (ORAL)	3.1%	OFF	No-Generic			
TEMAZEPAM 7.5 MG (ORAL)	0.0%	OFF	No-Generic			
TEMAZEPAM 22.5 MG (ORAL)	0.0%	OFF	No-Generic			

- Discussion: Ronald Diamond stated further analysis by the department should be performed to document how the drug triazolam is being prescribed. Rachel Currans-Henry stated that the department will refer to the DUR Board for further analysis and report back to the PA Committee. Ronald Diamond commented that one-time use is not the problem, such as the use for dental procedures. His concern is the ongoing prescribing can be a problem.
- Ronald Diamond made a motion to accept staff recommendations as presented.
  - Second –William Raduege
  - The vote was 7-2 in favor of the motion. Pat Towers and Alicia Walker oppose the motion.
  - Motion passes

STIMULANTS AND RELATED AGENTS						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
RITALIN SR (ORAL)	0.0%	ON	Yes			
METADATE CD (ORAL)	2.1%	ON	Yes			
DEXEDRINE SPANSULE (ORAL)	0.0%	ON	YES			
ADDERALL (ORAL)	0.1%	ON	Yes			
FOCALIN XR (ORAL)	4.6%	ON	Yes			
DEXMETHYLPHENIDATE (ORAL)	1.1%	ON	Yes-Generic			
METHYLPHENIDATE (ORAL)	6.7%	ON	Yes-Generic			
VYVANSE (ORAL)	15.0%	ON	Yes			
AMPHETAMINE SALT COMBO (ORAL)	17.7%	ON	No-Generic			
DAYTRANA (TRANSDERMAL)	0.8%	ON	Yes			
FOCALIN (ORAL)	0.0%	OFF	No			
RITALIN LA (ORAL)	0.1%	OFF	No			
METHYLIN CHEWABLE TABLETS (ORAL)	0.0%	ON	Yes			
METHYLPHENIDATE ER (ORAL)	1.2%	ON	Yes-Generic			
STRATTERA (ORAL)	3.4%	ON	Yes			
RITALIN LA 10 MG CAPSULE (ORAL)	0.0%	OFF	No			
RITALIN (ORAL)	0.0%	ON	Yes			
ADDERALL XR (ORAL)	25.5%	ON	Yes			
QUILLIVANT XR (ORAL)	0.1%	NR	Yes			
INTUNIV (ORAL)	4.2%	ON	Yes			
METHYLPHENIDATE ER (CONCERTA) (ORAL)	10.7%	ON	Yes-Generic			
DESOXYN (ORAL)	0.0%	OFF	No			
METHYLPHENIDATE CD (ORAL)	0.0%	OFF	No-Generic			
NUVIGIL (ORAL)	0.0%	OFF	No			
METHYLPHENIDATE CD (AG) (ORAL)	0.0%	OFF	No-Generic			
METHYLPHENIDATE ER (GEN	0.1%	OFF	No-Generic			

RITALIN LA) (ORAL)						
PROCENTRA (ORAL)	0.0%	OFF	Yes			
AMPHETAMINE SALT COMBO ER (TEVA, GLOBAL) (ORAL)	0.6%	OFF	No-Generic			
AMPHETAMINE SALT COMBO ER (ORAL)	0.2%	OFF	No-Generic			
DEXTROAMPHETAMINE TABLET (ORAL)	0.7%	ON	Yes-Generic			
METHYLIN SOLUTION (ORAL)	0.0%	OFF	No			
KAPVAY (ORAL)	0.4%	OFF	No			
DEXTROAMPHETAMINE SOLUTION (ORAL)	0.0%	NR	No-Generic			
ZENZEDI (ORAL)	0.0%	NR	No			
CONCERTA (ORAL)	3.0%	ON	No			
KAPVAY DOSE PACK (ORAL)	0.0%	OFF	No			
DEXTROAMPHETAMINE CAPSULE ER (ORAL)	1.2%	ON	No-Generic			
METHYLPHENIDATE SOLUTION (ORAL)	0.0%	OFF	No-Generic			
MODAFINIL (ORAL)	0.2%	OFF	No-Generic			
METHAMPHETAMINE (ORAL)	0.0%	OFF	No-Generic			

- Discussion: Rachel Currans-Henry noted that in the past Adderall and generic amphetamine salts were both preferred due to shortages. There is no longer a shortage issue, so we will no longer prefer the generic.
- Lawrence Fleming made a motion to accept staff recommendations as presented.
  - Second –William Raduege
  - All members were in favor of this motion.
  - Motion passes

ANTIHYPERTENSIVES, SYMPATHOLYTICS						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
CLONIDINE (ORAL)	63.1%	NR	Yes-Generic			
GUANFACINE (ORAL)	32.2%	NR	Yes-Generic			
METHYLDOPA (ORAL)	0.9%	NR	Yes-Generic			
RESERPINE (ORAL)	0.0%	NR	No-Generic			
CATAPRES-TTS (TRANSDERM)	0.2%	NR	Yes			
METHYLDOPA/HYDROCHLOROTHIAZIDE (ORAL)	0.0%	NR	No-Generic			
CLOPPRES (ORAL)	0.0%	NR	No-Generic			
CLONIDINE (TRANSDERM)	3.6%	NR	No-Generic			

- Discussion: None
- William Raduege made a motion to accept staff recommendations as presented.
  - Second –Pat Towers

- All members were in favor of this motion.
- Motion passes

ANXIOLYTICS						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
DIAZEPAM TABLET (ORAL)	16.7%	NR	Yes-Generic			
LORAZEPAM TABLET (ORAL)	30.3%	NR	Yes-Generic			
ALPRAZOLAM TABLET (ORAL)	39.8%	NR	Yes-Generic			
CHLORDIAZEPOXIDE (ORAL)	0.4%	NR	Yes-Generic			
BUSPIRONE (ORAL)	10.3%	NR	Yes-Generic			
CLORAZEPATE (ORAL)	0.5%	NR	Yes-Generic			
DIAZEPAM SOLUTION (ORAL)	0.6%	NR	Yes-Generic			
ALPRAZOLAM ER (ORAL)	0.9%	NR	Yes-Generic			
DIAZEPAM INTENSOL (ORAL)	0.1%	NR	No-Generic			
LORAZEPAM INTENSOL (ORAL)	0.2%	NR	Yes-Generic			
OXAZEPAM (ORAL)	0.2%	NR	No-Generic			
NIRAVAM (ORAL)	0.0%	NR	No-Generic			
ALPRAZOLAM INTENSOL (ORAL)	0.0%	NR	Yes-Generic			
ALPRAZOLAM ODT (ORAL)	0.1%	NR	No-Generic			
MEPROBAMATE (ORAL)	0.0%	NR	No-Generic			

- Discussion: Rachel Currans-Henry indicated that the MHDAG discussed grandfathering for this new drug class. Staff is recommending there would not be grandfathering. Ronald Diamond recommended pushing out the changes for this drug class to March to allow for a transition. Kim Wohler stated that providers will be notified of changes in December to take place in January. Implementing the new class January 1, 2014 would also coincide with benefit plan changes. In addition, only a few drugs are recommended as non-preferred, and they have low market share. Staff recommends continuity with the January 1, 2014 benefit plan changes.
- Mike Witkovsky indicated that alprazolam ODT was discussed at MHDA meeting and it would make sense to have this preferred to allow low dosages in geriatrics. Lynn Radmer stated that alprazolam intensol comes with a dropper and is accurate to 0.25mg and the product should be mixed in liquids or semi-solid foods. Rick Pope indicated that there is very low utilization in alprazolam ODT. Michael Witkovsky stated concern with dosing of 0.125mg. Rachel Currans-Henry stated that if department finds through research that a low dose ODT product is available, the department would consider a preferred status.
- Michael Witkovsky made a motion to accept staff recommendations as presented.
  - Second –William Raduege
  - All members were in favor of this motion.
  - Motion passes

ANTIPSORIATICS, ORAL						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
SORIATANE (ORAL)	96.6%	NR	Yes			
OXSORALEN-ULTRA (ORAL)	3.4%	NR	Yes			
8-MOP (ORAL)	0.0%	NR	Yes			
ACITRETIN (AG) (ORAL)	0.0%	NR	No-Generic			
ACITRETIN (ORAL)	0.0%	NR	No-Generic			

- Discussion: None
- Catherine Decker made a motion to accept staff recommendations as presented.
  - Second –William Raduege
  - All members were in favor of this motion.
  - Motion passes

IMMUNOMODULATORS, TOPICAL						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
ALDARA (TOPICAL)	0.2%	NR	Yes			
IMIQUIMOD (TOPICAL)	99.7%	NR	No-Generic			
ZYCLARA (TOPICAL)	0.2%	NR	No			

- Discussion: None
- William Raduege made a motion to accept staff recommendations as presented.
  - Second –Pat Towers
  - All members were in favor of this motion.
  - Motion passes